TLX vs EXEL vs RNW

For growth investors, Telix Pharmaceuticals Limited (TLX) is the stronger pick with 55.

8% revenue growth year-over-year, versus 7. 0% for Exelixis, Inc. (EXEL). Exelixis, Inc. (EXEL) offers the better valuation at 17. 3x trailing P/E (13. 8x forward), making it the more compelling value choice. Analysts rate Telix Pharmaceuticals Limited (TLX) a "Buy" — based on 5 analyst ratings — the highest consensus in this comparison. The "better buy" depends entirely on your goals: growth investors should weight revenue trajectory, value investors should weight P/E and PEG, and income investors should weight dividend yield and streak.

On trailing P/E, Exelixis, Inc.

(EXEL) is the cheapest at 17. 3x versus Telix Pharmaceuticals Limited at 105. 7x. On forward P/E, ReNew Energy Global Plc is actually cheaper at 0. 4x — notably different from the trailing picture, reflecting expected earnings growth.

Over the past 5 years, Exelixis, Inc.

(EXEL) delivered a total return of +93. 0%, compared to -43. 3% for ReNew Energy Global Plc (RNW). Over 10 years, the gap is even starker: EXEL returned +872. 9% versus RNW's -48. 5%. Past returns do not guarantee future results, and the stock with the higher historical return may already have its best growth priced in.

By beta (market sensitivity over 5 years), ReNew Energy Global Plc (RNW) is the lower-risk stock at 0.

69β versus Telix Pharmaceuticals Limited's 0. 88β — meaning TLX is approximately 27% more volatile than RNW relative to the S&P 500. On balance sheet safety, Exelixis, Inc. (EXEL) carries a lower debt/equity ratio of 8% versus 6% for ReNew Energy Global Plc — giving it more financial flexibility in a downturn.

By revenue growth (latest reported year), Telix Pharmaceuticals Limited (TLX) is pulling ahead at 55.

8% versus 7. 0% for Exelixis, Inc. (EXEL). On earnings-per-share growth, the picture is similar: Telix Pharmaceuticals Limited grew EPS 769. 6% year-over-year, compared to 10. 1% for ReNew Energy Global Plc. Over a 3-year CAGR, TLX leads at 368. 9% annualised revenue growth. Higher growth typically commands a higher valuation multiple — check whether the premium P/E or P/S is justified by the growth rate using the PEG ratio.

Exelixis, Inc.

(EXEL) is the more profitable company, earning 33. 7% net margin versus 3. 9% for ReNew Energy Global Plc — meaning it keeps 33. 7% of every revenue dollar as bottom-line profit. Operating margin tells a similar story: RNW leads at 53. 5% versus 10. 5% for TLX. At the gross margin level — before operating expenses — EXEL leads at 96. 4%, reflecting greater pricing power or product mix advantage. Stronger margins indicate durable pricing power, lower cost of revenue, or higher mix of software/services. They are one of the clearest signs of business quality.

On forward earnings alone, ReNew Energy Global Plc (RNW) trades at 0.

4x forward P/E versus 167. 1x for Telix Pharmaceuticals Limited — 166. 7x cheaper on a one-year earnings basis. Analyst consensus price targets imply the most upside for TLX: 59. 2% to $17. 00.

None of the stocks in this comparison currently pay a material dividend.

All are effectively zero-yield and should be held for capital appreciation rather than income.

For long-horizon retirement investors, Exelixis, Inc.

(EXEL) is the stronger choice — it scores higher on the combination of lower volatility, dividend reliability, and long-term compounding (low volatility (β 0. 86), +872. 9% 10Y return). Both have compounded well over 10 years (EXEL: +872. 9%, TLX: -29. 5%), confirming both are viable long-term holds — but the lower-volatility option typically results in less emotional selling during corrections. Retirement portfolios generally favour predictability over maximum returns. Consult a financial advisor before making allocation decisions.

These companies operate in different sectors (TLX (Healthcare) and EXEL (Healthcare) and RNW (Utilities)), which means they face different economic cycles, regulatory environments, and macro sensitivities — making direct comparison nuanced.

In terms of investment character: TLX is a small-cap high-growth stock; EXEL is a mid-cap deep-value stock; RNW is a small-cap high-growth stock. These fundamental differences mean investors should not choose between them on a single metric — the "better stock" depends entirely on which of these characteristics aligns with your investment strategy.